![Sandoz Group Ag](/common/images/company/L_0SAN.png)
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches...
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar...
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing...
Sandoz reports first quarter 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5...
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG All proposals of Board of Directors approvedGilbert Ghostine re-elected as...
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches...
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules...
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.